<DOC>
	<DOC>NCT00219310</DOC>
	<brief_summary>This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.</brief_summary>
	<brief_title>RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>• Patients who are immunocompetent and who have had 4 or more episodes of Recurrent Genital Herpes (RGH) in the last 12 months. Patients with active HSV2 or HSV1 infection as confirmed by Polymerase Chain Reaction (PCR). Patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes • Female patients who are pregnant or breastfeeding. Current, history or suspicion of liver disease or kidney disease. HIV infected (as confirmed by positive HIV serology). Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Recurrent Genital Herpes (RGH), famciclovir, episodic treatment, suppressive treatment, Polymerase Chain Reaction (PCR).</keyword>
</DOC>